Notice
Recent Posts
Recent Comments
일 | 월 | 화 | 수 | 목 | 금 | 토 |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | |
7 | 8 | 9 | 10 | 11 | 12 | 13 |
14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 |
28 | 29 | 30 |
Tags
- China Construction Bank
- Japan
- LOI
- CCB
- Merger
- taiwan
- acquisition
- Bank
- Investment
- Acquistion
- sk
- private equity
- Confidential Agreement
- M&A
- case study
- OTCBB
- hong kong
- nda
- Japan Tobacco
- buyout
- PEF
- Malaysia
- Korea
- capital gate
- securities
- Letter of intent
- cgi korea
- Korea M&A
- CA
- China
Archives
- Today
- Total
Korea M&A Corporation
GS’ acquisition of Hugel to change domestic BTX, bio markets
As the GS consortium is certain to acquire Korea's botulinum toxin (BTX) developer, Hugel, industry watchers are paying keen attention to how the acquisition would change the company and the domestic BTX and bio markets. The four-party private equity fund formed by the GS Group, also participated in by IMM Investment, China's CBC Group, and the United Arab Emirates (UAE) Mubadala Investment Comp..
News/M&A
2021. 8. 23. 10:23